J. Buell

发表

Mutation-Derived Neoantigens for Cancer Immunotherapy

J. Castle, Mohamed Uduman, S. Pabla, 2019, Front. Immunol..

Selective FcγR Co-engagement on APCs Modulates the Activity of Therapeutic Antibodies Targeting T Cell Antigens.

L. Swiech, B. Croker, D. Savitsky, 2018, Cancer cell.

Correction to: Angiosarcoma patients treated with immune checkpoint inhibitors: a case series of seven patients from a single institution

J. Castle, Mohamed Uduman, A. Rosenberg, 2019, Journal of Immunotherapy for Cancer.

Angiosarcoma patients treated with immune checkpoint inhibitors: a case series of seven patients from a single institution

J. Castle, Mohamed Uduman, A. Rosenberg, 2019, Journal of Immunotherapy for Cancer.

Toxicological and pharmacological assessment of AGEN1884, a novel human IgG1 anti-CTLA-4 antibody

D. Underwood, J. Wolchok, M. Findeis, 2018, PloS one.

Neoantigen Synthetic Peptide Vaccine for Multiple Myeloma Elicits T Cell Immunity in a Pre-Clinical Model

J. Castle, Mohamed Uduman, M. Findeis, 2017 .

377 AGEN2373 is a CD137 agonist antibody designed to leverage optimal CD137 and FcγR co-targeting to promote antitumor immunologic effects

D. Underwood, A. Tolcher, M. Findeis, 2020 .

Phase I/II, open-label, multiple ascending dose trial of AGEN2034, an anti-PD-1 monoclonal antibody, in advanced solid malignancies: Results of dose escalation in advanced cancer and expansion cohorts in subjects with relapsed/refractory cervical cancer.

C. Drescher, H. Youssoufian, O. Shebanova, 2018, Annals of Oncology.

Phase 1/2 open-label, multiple ascending dose trial of AGEN2034, an anti-PD-1 monoclonal antibody, in advanced solid malignancies: Results of dose escalation.

H. Youssoufian, O. Shebanova, Joyce F. Liu, 2018 .

Molecular mechanism of phosphopeptide neoantigen immunogenicity

M. Findeis, Y. Patskovsky, B. Joshi, 2023, Nature communications.

Selective FcγR Co-engagement on APCs Modulates the Activity of Therapeutic Antibodies Targeting T Cell Antigens.

L. Swiech, B. Croker, D. Savitsky, 2018, Cancer cell.

253 Anti-TIGIT antibodies require enhanced FcγR co-engagement for optimal T and NK cell-dependent anti-tumor immunity

E. Paltrinieri, D. Savitsky, J. Buell, 2020 .

Abstract 4703: INCAGN1949, an anti-OX40 antibody with an optimal agonistic profile and the ability to selectively deplete intratumoral regulatory T cells

L. Swiech, R. Stein, T. Merghoub, 2017 .

Phase I/II, open-label, multiple ascending dose trial of AGEN2034, an anti-PD-1 monoclonal antibody, in advanced solid malignancies: Results of dose escalation in advanced cancer and expansion cohorts in subjects with relapsed/refractory cervical cancer.

C. Drescher, H. Youssoufian, O. Shebanova, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.